CPHI
China Pharma Holdings, Inc.
There isn't enough reported data to score CPHI yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CPHI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Weak |
CPHI's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CPHI PE Valuation
CPHI has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CPHI Forward outlook
There aren't enough analyst estimates for CPHI to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CPHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.42 | +$1.08 |
| Q1 2026 | -$0.54 | +$1.70 |
| Q4 2025 | -$0.74 | +$1.96 |
| Q3 2022 | -$35.00 | +$10.00 |
| Q2 2022 | -$35.00 | +$10.00 |
| Q1 2022 | -$35.00 | $0.00 |
| Q4 2021 | -$35.00 | $0.00 |
| Q3 2021 | -$45.00 | +$190.00 |
CPHI lost $0.42 per share over the past year, a smaller loss than the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CPHI on earnings quality, reporting a profit while its opponent remains loss making.
CPHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $948.3K | -7.5% |
| Q1 2026 | $983.5K | -13% |
| Q4 2025 | $1.2M | +8.1% |
| Q3 2025 | $756.2K | -31% |
| Q2 2025 | $1M | +11% |
| Q1 2025 | $1.1M | -17% |
| Q4 2024 | $1.1M | -47% |
| Q3 2024 | $1.1M | -39% |
CPHI's revenue has slid since its 2020 peak: $948,340 last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -151% | -87 points |
| Q1 2026 | -114% | -47 points |
| Q4 2025 | -98% | +7.6 points |
| Q3 2025 | -83% | +16 points |
| Q2 2025 | -64% | +87 points |
| Q1 2025 | -67% | +0.1 points |
| Q4 2024 | -105% | -50 points |
| Q3 2024 | -99% | -59 points |
CPHI's operating margin was −151% last quarter, down 87 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CPHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CPHI on profitability, with a higher operating margin.
CPHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2025 | -$237.6K | -$190.6K |
| Q2 2025 | $291.1K | +$363.9K |
| Q1 2025 | -$116.1K | +$469K |
| Q3 2024 | -$47K | -105% |
| Q2 2024 | -$72.7K | +$143.7K |
| Q1 2024 | -$585.2K | +$883.1K |
| Q4 2023 | -$22.3K | -104% |
| Q3 2023 | $1M | +$1M |
CPHI has the stronger cash trend. Its trailing FCF is up 110% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CPHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +58% | +14.9M shares |
| 1 year | +1142% | +37.3M shares |
| 3 years | +40409% | +40.4M shares |
| 5 years | +46392% | +40.4M shares |
| Available history | +46392% | +40.4M shares |
CPHI has 41M diluted shares, up 1142% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CPHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CPHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 1,068.6x | High |
| Q1 2022 | 217.7x | High |
| Q4 2021 | 20.8x | High |
| Q1 2021 | 92.7x | High |
| Q4 2020 | 42.3x | High |
CPHI's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CPHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 5.4 | Oversold |
CPHI's weekly RSI is 41 (neutral) and its Stochastic is 5 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CPHI PE vs Healthcare Sector
CPHI has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CPHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 18% below |
| 20 week MA | $0.84 | 33% below |
| 50 week MA | $0.86 | 35% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $5.78 | 90% below |
CPHI is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CPHI on trend strength, trading above more of its moving averages.
CPHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $121.5 | $223.8 | +84% |
| 2021 | $223.8 | $215.1 | -3.9% |
| 2022 | $215.1 | $58.3 | -73% |
| 2023 | $58.3 | $6.05 | -90% |
| 2024 | $6.05 | $2.10 | -65% |
| 2025 | $2.10 | $1.29 | -39% |
| 2026 YTD | $1.29 | $0.56 | -57% |
CPHI has finished five years in a row lower, and it's down 57% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CPHI on returns for 2026, with the stronger performance.